Lunit to Present c-MET, HER2 AI Biomarker Studies at AACR 2026
[Song Young Doo, Edaily Reporter] Medical AI company Lunit announced on April 20 that it will present six research abstracts at the AACR 2026, held in San Diego, U.S.
The study explores the relationship between c-MET (hepatocyte growth factor receptor) expression and the tumor microenvironment in non-small cell lung cancer(NSCLC).
The research team analyzed 25,674 NSCLC samples using Lunit SCOPE IO and Lunit SCOPE uIHC to assess immune cell distribution surrounding tumor cells based on c-MET expression levels.
뉴스픽의 주요 문장 추출 기술을 사용하여 “이데일리” 기사 내용을 3줄로 요약한 결과입니다. 일부 누락된 내용이 있어 전반적인 이해를 위해서는 본문 전체 읽기를 권장합니다.
